SCHEMBL650310

SCHEMBL650310

CCCCn1c(-c2ccccc2)nc(C(F)(F)F)c1CN(Cc1ccc2c(c1)CCC(=O)N2)Cc1ccc2c(c1)OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.52
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
RAB9A P51151 1/20 0.35
HIF1A Q16665 1/20 0.35
UBE2M P61081 3/20 0.35
DCUN1D1 Q96GG9 3/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ADRA2A P08913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649695 0.92 C5AR1 (0.59) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL648290 0.89 CRHR1 (0.41) C5AR1ALDH1A1LMNATSHRGAA
SCHEMBL648841 0.88 C5AR1 (0.65) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL650118 0.87 C5AR1 (0.63) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL1912843 0.86 C5AR1 (0.57) C5AR1ALDH1A1LMNASMN1; SMN2L3MBTL1
SCHEMBL1912842 0.86 C5AR1 (0.62) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL648380 0.85 CRHR1 (0.37) C5AR1LMNATSHR
SCHEMBL649792 0.84 C5AR1 (0.62) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL1912838 0.83 C5AR1 (0.57) C5AR1ALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL649896 0.83 C5AR1 (0.57) C5AR1ALDH1A1LMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed